abbott surestep™ multi-drug one step multi-line screen test (urine)
unison collaborative pte. ltd. - clinical toxicology - a rapid, one step screening test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine: amphetamine, cocaine, marijuana (thc), morphine, phencyclidine, benzodiazepines, methadone, opiate, barbiturate, methamphetamine, methylenedioxy-methamphetamine, and tricyclic antidepressants.
abbott surestep™ multi-drug one step screen test (urine)
unison collaborative pte. ltd. - clinical toxicology - a rapid, one step screening test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine: buprenorphine, ketamine, cocaine, cotinine, amphetamine, marijuana (thc), morphine, benzodiazepines, methamphetamine, methylenedioxy-methamphetamine, phencyclidine, tricyclic antidepressants, barbiturates, methadone, and oxycodone.
co-amoxiclav teva 500 mg/100 mg powder for solution for injection/infusion
teva pharma b.v. - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 500 mg/100 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor
co-amoxiclav teva 1000 mg/200 mg powder for solution for injection/infusion
teva pharma b.v. - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 1000 mg/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor
amoxi-clavulan aurobindo 875 mg/125 mg filmtabletten
amoxi-clavulan aurobindo 500 mg/125 mg filmtabletten
amoxicillin and clavulanate potassium powder, for suspension
clinical solutions wholesale - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 200 mg in 5 ml - to reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis
amoxicillin/clavulanic acid krka 500 mg/125 mg film-coated tablets
krka, d.d., novo mesto - amoxicillin; clavulanic acid - film-coated tablet - 500 mg/ 125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor - : antibacterials for systemic use, combinations of penicillins, incl. beta-lactamase inhibitors - - acute bacterial sinusitis (adequately diagnosed) - acute otitis media - acute exacerbations of chronic bronchitis (adequately diagnosed) - community acquired pneumonia - cystitis - pyelonephritis - skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. - bone and joint infections, in particular osteomyelitis.
amoxil- amoxicillin tablet, film coated
direct rx - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - 1.1 infections of the ear, nose, and throat amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae, staphylococcus spp., or haemophilus influenzae. 1.2 infections of the genitourinary tract amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis, or enterococcus faecalis. 1.3 infections of the skin and skin structure amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli. 1.4 infections of the lower respiratory tract amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolat
amoxicillin tablet, film coated
direct rx - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - 1.1 infections of the ear, nose, and throat amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae, staphylococcus spp., or haemophilus influenzae. 1.2 infections of the genitourinary tract amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis, or enterococcus faecalis. 1.3 infections of the skin and skin structure amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli. 1.4 infections of the lower respiratory tract amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoni